These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 38856215)

  • 1. Y-90 Radioembolization and PD-1 Inhibitor as Neoadjuvant Treatment in Hepatocellular Carcinoma.
    Li Q; Wang X; Li D; Liu Y; Liu K; Liang J; Sun J; Jiang Q; Li J; Liu Z; Gong J; Xiang L; Jia Z; Chen Z; Cao M; Jiang Y
    J Vis Exp; 2024 May; (207):. PubMed ID: 38856215
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A simple method for estimating dose delivered to hepatocellular carcinoma after yttrium-90 glass-based radioembolization therapy: preliminary results of a proof of concept study.
    Kokabi N; Galt JR; Xing M; Camacho JC; Barron BJ; Schuster DM; Kim HS
    J Vasc Interv Radiol; 2014 Feb; 25(2):277-87. PubMed ID: 24461133
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Accuracy and reproducibility of a cone beam CT-based virtual parenchymal perfusion algorithm in the prediction of SPECT/CT anatomical and volumetric results during the planification of radioembolization for HCC.
    Derbel H; Krichen M; Chalaye J; Saccenti L; Van der Sterren W; Muris AH; Lerman L; Galletto A; Zaarour Y; Luciani A; Kobeiter H; Tacher V
    Eur Radiol; 2023 May; 33(5):3510-3520. PubMed ID: 36651956
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Single-Session Ablative Transarterial Radioembolization for Patients with Hepatocellular Carcinoma to Streamline Care: An Initial Experience.
    Berman ZT; Pianka K; Qaseem Y; Redmond J; Minocha J
    Cardiovasc Intervent Radiol; 2024 Sep; 47(9):1239-1245. PubMed ID: 38977445
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Streamlining radioembolization in UNOS T1/T2 hepatocellular carcinoma by eliminating lung shunt estimation.
    Gabr A; Ranganathan S; Mouli SK; Riaz A; Gates VL; Kulik L; Ganger D; Maddur H; Moore C; Hohlastos E; Katariya N; Caicedo JC; Kalyan A; Lewandowski RJ; Salem R
    J Hepatol; 2020 Jun; 72(6):1151-1158. PubMed ID: 32145255
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of absorbed doses to the tumoral and non-tumoral liver in HCC patients undergoing
    Noipinit N; Sukprakun C; Siricharoen P; Khamwan K
    Ann Nucl Med; 2024 Mar; 38(3):210-218. PubMed ID: 38142421
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of the survival and tolerability of radioembolization in elderly vs. younger patients with unresectable hepatocellular carcinoma.
    Golfieri R; Bilbao JI; Carpanese L; Cianni R; Gasparini D; Ezziddin S; Paprottka PM; Fiore F; Cappelli A; Rodriguez M; Ettorre GM; Saltarelli A; Geatti O; Ahmadzadehfar H; Haug AR; Izzo F; Giampalma E; Sangro B; Pizzi G; Notarianni E; Vit A; Wilhelm K; Jakobs TF; Lastoria S;
    J Hepatol; 2013 Oct; 59(4):753-61. PubMed ID: 23707371
    [TBL] [Abstract][Full Text] [Related]  

  • 8. SPECT/CT with 99mTc-MAA in radioembolization with 90Y microspheres in patients with hepatocellular cancer.
    Hamami ME; Poeppel TD; Müller S; Heusner T; Bockisch A; Hilgard P; Antoch G
    J Nucl Med; 2009 May; 50(5):688-92. PubMed ID: 19372479
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Quantitative Imaging Biomarkers for
    Schobert I; Chapiro J; Nezami N; Hamm CA; Gebauer B; Lin M; Pollak J; Saperstein L; Schlachter T; Savic LJ
    J Nucl Med; 2019 Aug; 60(8):1066-1072. PubMed ID: 30655331
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Measurement of the Tumor-to-Normal Ratio for Radioembolization of Hepatocellular Carcinoma: A Prospective Study Comparing 2-Dimensional Perfusion Angiography, Technetium-99m Macroaggregated Albumin, and Yttrium-90 SPECT/CT.
    Brunson CP; McGregor HJ; Hennemeyer CT; Patel MV; Woodhead GJ; Young SJ
    J Vasc Interv Radiol; 2024 Jan; 35(1):94-101. PubMed ID: 37783268
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical and Dosimetric Implications of Calculating Lung Shunt Fraction for Hepatic
    Struycken L; Patel M; Kuo P; Hennemeyer C; Woodhead G; McGregor H
    AJR Am J Roentgenol; 2022 Apr; 218(4):728-737. PubMed ID: 34704460
    [No Abstract]   [Full Text] [Related]  

  • 12. Relationship of Tumor Radiation-absorbed Dose to Survival and Response in Hepatocellular Carcinoma Treated with Transarterial Radioembolization with
    Hermann AL; Dieudonné A; Ronot M; Sanchez M; Pereira H; Chatellier G; Garin E; Castera L; Lebtahi R; Vilgrain V;
    Radiology; 2020 Sep; 296(3):673-684. PubMed ID: 32602828
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Correlation of C-arm CT acquired parenchymal blood volume (PBV) with 99mTc-macroaggregated albumin (MAA) SPECT/CT for radioembolization work-up.
    Weissinger M; Vogel J; Kupferschläger J; Dittmann H; Castaneda Vega SG; Grosse U; Artzner C; Nikolaou K; la Fougere C; Grözinger G
    PLoS One; 2020; 15(12):e0244235. PubMed ID: 33378338
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Characteristics of primary and secondary hepatic malignancies associated with hepatopulmonary shunting.
    Gaba RC; Zivin SP; Dikopf MS; Parvinian A; Casadaban LC; Lu Y; Bui JT
    Radiology; 2014 May; 271(2):602-12. PubMed ID: 24533871
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Correlation of Technetium-99m Macroaggregated Albumin and Yttrium-90 Glass Microsphere Biodistribution in Hepatocellular Carcinoma: A Retrospective Review of Pretreatment Single Photon Emission CT and Posttreatment Positron Emission Tomography/CT.
    Haste P; Tann M; Persohn S; LaRoche T; Aaron V; Mauxion T; Chauhan N; Dreher MR; Johnson MS
    J Vasc Interv Radiol; 2017 May; 28(5):722-730.e1. PubMed ID: 28238581
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Yttrium-90 Radioembolization as a Salvage Treatment following Chemoembolization for Hepatocellular Carcinoma.
    Johnson GE; Monsky WL; Valji K; Hippe DS; Padia SA
    J Vasc Interv Radiol; 2016 Aug; 27(8):1123-9. PubMed ID: 27321889
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical impact of (99m)Tc-MAA SPECT/CT-based dosimetry in the radioembolization of liver malignancies with (90)Y-loaded microspheres.
    Garin E; Rolland Y; Laffont S; Edeline J
    Eur J Nucl Med Mol Imaging; 2016 Mar; 43(3):559-75. PubMed ID: 26338177
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dosimetry based on 99mTc-macroaggregated albumin SPECT/CT accurately predicts tumor response and survival in hepatocellular carcinoma patients treated with 90Y-loaded glass microspheres: preliminary results.
    Garin E; Lenoir L; Rolland Y; Edeline J; Mesbah H; Laffont S; Porée P; Clément B; Raoul JL; Boucher E
    J Nucl Med; 2012 Feb; 53(2):255-63. PubMed ID: 22302962
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Indicators of Lung Shunt Fraction Determined by Technetium-99 m Macroaggregated Albumin in Patients with Hepatocellular Carcinoma.
    Kallini JR; Gabr A; Hickey R; Kulik L; Desai K; Yang Y; Gates VL; Riaz A; Salem R; Lewandowski RJ
    Cardiovasc Intervent Radiol; 2017 Aug; 40(8):1213-1222. PubMed ID: 28280976
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Metabolic activity assessment by
    Kim DY; Lee HW; Kang W; Kim GM; Won JY; Yun M
    J Gastroenterol Hepatol; 2021 Jun; 36(6):1679-1684. PubMed ID: 33226706
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.